Intel Surges Past $100 on Best Month in 55-Year Nasdaq History
Intel’s stock more than doubled in April 2026 — its best month in 55 years — as Q1 earnings beat expectations and AI server CPU demand rewrites the semiconductor narrative.
stock market
AXT Jumps 21% as AI Optical Demand Drives 39% Revenue Growth
AXT Inc. (AXTI) surged 21% after Q1 2026 revenue rose 39% year-over-year to $26.9M, fueled by AI data-center demand for indium phosphide substrates.
Roblox Drops 18% Despite Revenue Beat as Child Safety Costs Weigh
Roblox Q1 2026 revenue rose 39% to $1.44B, but widening losses and a guidance cut tied to child safety measures sent shares tumbling 18% on May 1.
Reddit Q1 2026: Revenue Jumps 69%, AI Data Bet Pays Off
Reddit posted $663M in Q1 2026 revenue — up 69% YoY — with ad revenue surging 74% and EPS hitting $1.01. The platform’s AI data edge is real and accelerating.
Apple Q2 2026: $111B Revenue, iPhone 17 Demand Breaks Records
Apple beat Q2 2026 estimates with $111.2B revenue (+17% YoY), EPS of $2.01 (+22%), a China upside of $1.6B above consensus, and a new $100B buyback authorization.
Twilio Surges 24% as Q1 Revenue Jumps 20%, AI Voice Ramps
Twilio stock climbed nearly 24% after Q1 2026 revenue grew 20% year-over-year to $1.4 billion, with GAAP profitability surging and full-year guidance raised.
What Is Post-Earnings Drift? Whisper Numbers Explained
Learn why stocks keep moving after earnings reports. Understand whisper numbers, post-earnings drift (PEAD), and how these forces drive market moves every quarter.
Atlassian Jumps 24% on Q3 Earnings Blowout and AI Momentum
Atlassian stock surged 24% after Q3 FY2026 results crushed estimates — revenue hit $1.79B (+32% YoY), non-GAAP EPS of $1.75 beat by 34%, and Rovo AI credits grew 20%+ monthly.
Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge
Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.
Eli Lilly Q1 2026: Revenue Surges 56% as GLP-1 Boom Deepens
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.